September 29, 2025: Kapiva, a healthcare brand focused on Ayurveda-based products, has raised a significant $60 million in its Series D funding round. This capital infusion aims to amplify the company’s research and development, fortify manufacturing capabilities, and establish a health-tech platform to offer more personalized care, marking a key milestone in its growth trajectory.
The latest funding round underscores both the accelerating interest in Ayurveda and the growing recognition of personalized wellness solutions in global markets. Kapiva’s annual growth rate of over 80% in the past three years and an impressive annual revenue run rate of ₹5.5 billion (~$66 million) signals strong market demand for its diverse range of products. From diabetes care and sports nutrition to liver function and general wellness, Kapiva’s product portfolio is tapping into the burgeoning wellness industry.
Kapiva’s Funding to Accelerate Global Expansion and Innovation in Ayurveda-Based Wellness
This growth is not just about expanding product lines; it’s also about expanding reach. Kapiva’s products, sold via e-commerce, its own website, and through 40,000+ retail outlets in India, now also cater to international markets, including the U.S., Middle East, and Europe. This funding will fuel its ambition to further penetrate these regions while advancing its health-tech innovations.
In a sector where consumer preferences are shifting towards personalized care, the company’s pivot to incorporate digital solutions is a timely and smart move. This alignment with modern health-tech trends positions Kapiva well to become a dominant player in the health and wellness space.
The Series D round was led by 360 ONE Asset and Vertex Growth, both prominent players in venture capital investment. The round also saw participation from existing investors Vertex Ventures Southeast Asia and India and 3one4 Capital. Additionally, a portion of the funds was allocated for exits to earlier investors, showing the success and stability of the company’s investor-backed journey.
This latest round of funding will drive Kapiva’s R&D efforts, enabling the company to enhance its product formulations and build out its tech infrastructure. It will also boost its brand investments, allowing the company to increase its market presence and offer consumers more personalized solutions through an integrated health-tech platform.
Kapiva’s growth trajectory has been marked by its founder-driven vision. Established in 2016 by Ameve Sharma, a scion of the Baidyanath Group known for its ayurvedic legacy, and Shrey Badhani, a former consultant at Bain & Co., the company has steadily captured market attention. The recent promotions of Shantanu and Anuj Sharma to co-founders further solidify Kapiva’s leadership strength as it pushes forward with its ambitious plans.
Kapiva’s robust funding history reflects investor confidence in its business model. In 2021, the company raised capital from Vertex Ventures, Fireside Ventures, Jetty Ventures India, and Rishabh Mariwala. Earlier in 2019, Kapiva secured a $2.5 million investment from Fireside Ventures, marking its early stages of growth.
As demand for natural wellness products continues to surge, Ayurvedic solutions are increasingly seen as a viable alternative to conventional medicine. The company’s ability to leverage both traditional knowledge and modern technology gives it a unique competitive edge. Kapiva’s strategic expansion into health-tech further strengthens its position in the wellness market, poised for success on a global scale.
